Stephens Reaffirms “Overweight” Rating for Establishment Labs (NASDAQ:ESTA)

Establishment Labs (NASDAQ:ESTA)‘s stock had its “overweight” rating reissued by stock analysts at Stephens in a report issued on Thursday,Benzinga reports. They presently have a $52.00 price target on the stock. Stephens’ price objective indicates a potential upside of 21.30% from the company’s current price.

Establishment Labs Stock Up 0.8 %

Shares of NASDAQ:ESTA opened at $42.87 on Thursday. The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. The stock has a fifty day simple moving average of $37.45 and a two-hundred day simple moving average of $41.34. Establishment Labs has a 12-month low of $28.16 and a 12-month high of $60.12. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of -16.62 and a beta of 1.12.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.34). Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The company had revenue of $44.51 million during the quarter, compared to analysts’ expectations of $44.45 million. On average, research analysts anticipate that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Establishment Labs

A number of hedge funds have recently added to or reduced their stakes in ESTA. Barclays PLC increased its holdings in shares of Establishment Labs by 9,643.3% in the 3rd quarter. Barclays PLC now owns 31,471 shares of the company’s stock worth $1,362,000 after purchasing an additional 31,148 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Establishment Labs by 89.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 41,351 shares of the company’s stock valued at $1,789,000 after buying an additional 19,531 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in Establishment Labs in the 4th quarter worth about $12,898,000. Vestal Point Capital LP purchased a new position in Establishment Labs in the 3rd quarter worth about $1,731,000. Finally, Bamco Inc. NY lifted its stake in Establishment Labs by 13.6% during the 3rd quarter. Bamco Inc. NY now owns 489,386 shares of the company’s stock valued at $21,176,000 after acquiring an additional 58,611 shares during the period. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.